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H epatitis C virus (HCV) infection has become the most common cause of cirrhosis and hepatocellular carcinoma in the Western world. End-stage liver disease because of HCV infection is the leading indication of liver transplantation (LT). Unfortunately, HCV infection recurs universally after LT. 1 Moreover, one-third of the patients present an accelerated course of hepatitis C recurrence during the first 5 years after LT. 2 As a consequence, hepatitis C recurrence is the primary cause of graft loss and reduction in patient survival. 3 Identifying patients with progressive hepatitis C recurrence early after LT may be relevant to adopt therapeutic decisions because antiviral treatment could probably decrease or even interrupt fibrosis progression in patients with progressive hepatitis C recurrence. 4 Progression of liver fibrosis results from an imbalance between production, deposition, and degradation of the extracellular matrix, leading to portal hypertension and clinical decompensation. Early histologic damage after transplantation identifies patients with progressive hepatitis C recurrence. 5 However, the variability of liver biopsy in assessing liver fibrosis is a major problem in persons with rapid disease progression. 6 In contrast, the hepatic venous pressure gradient (HVPG) has recently been shown to be even more accurate than liver biopsy at identifying patients at risk of clinical decompensation in the transplantation setting. 7 However, liver biopsy and HVPG determination are invasive methods with associated morbidity. 8 There has recently been an increasing interest in noninvasive methods to assess the degree of liver fibrosis after LT. Transient elastography (TE), a new noninvasive method to measure liver stiffness (LSM), has proved to be useful in assessing liver fibrosis in patients with chronic hepatitis C. 9 This method has been recently shown to be useful to assess liver fibrosis stage (F Ն 2) 10 and portal hypertension (HVPG Ն 6 mm Hg) 11 in patients with HCV who received a liver transplant. "Indirect" serologic tests 12, 13 have shown limitations in the transplantation setting because some of the variables included can be altered by causes not related to fibrosis progression. Preliminary data in the LT setting suggest that the use of "direct" biomarkers of fibrosis might be useful to identify patients infected with HCV with rapid fibrosis progression after LT. 14 Although liver fibrosis is a local reaction of the liver to chronic injury, serum concentrations of fibrogenic cytokines, extracellular matrix proteins, and degradation products are markedly increased in cases of advanced fibrosis. Activation of hepatic stellate cells is a dominant event in hepatic fibrogenesis. Cisneros et al 15 recently reported that levels of activated hepatic stellate cells by computer-based morphometric analysis of ␣-smooth muscle actin-positive cells and hepatic transforming growth factor ␤-1 expression by immunohistochemistry identify patients with advanced fibrosis after LT. Markers linked to matrix deposition are generally based on detection of carboxy and amino terminal procollagen peptides such as amino-terminal propeptide of type III procollagen (PIIINP). 16 Hyaluronic acid (HA), another marker associated with matrix deposition, shows good diagnostic accuracy as a marker of liver cirrhosis in patients with HCV. 16, 17 Moreover, other markers associated with matrix degradation are a family of enzymes called matrix metalloproteinases, and their inhibitors such as tissue inhibitors of matrix metalloproteinases regulate degradation of collagen. These markers of matrix degradation have also been used to assess the severity of liver fibrosis because their expression correlates with collagen turnover. Rosenberg et al 18 have demonstrated that the combination of 3 direct biomarkers of fibrosis (PIIINP, HA, and tissue inhibitors of matrix metalloproteinases type-1 [TIMP-1]) is useful to identify patients with advanced fibrosis (F Ն 3) and cirrhosis (F4). These 3 biomarkers have recently been validated in non-alcoholic fatty liver disease, 19, 20 primary biliary cirrhosis, 21 alcoholic liver disease, 22 and patients infected with HCV during antiviral treatment. 23 The aim of our study was to investigate whether repeated measurements of 3 serum fibrosis markers (PIIINP, HA, and TIMP-1) at 3, 6, and 12 months after LT can identify patients at risk of developing significant fibrosis and portal hypertension in a prospectively followed cohort of patients with HCV who received a liver transplant. In addition, we compared the diagnostic accuracy of serum fibrosis markers with that of routine laboratory tests to identify progressive HCV recurrence.
Patients and Methods Patients
One hundred ninety-five consecutive liver transplant recipients with hepatitis C recurrence, who were seen at the Hospital Clínic of Barcelona from May 2000 to July 2006, were considered for the study. Exclusion criteria were: suboptimal biopsies, graft or patient survival shorter than 12 months after LT, moderate or severe acute graft rejection during the first 3 months, biliary complications, and antiviral treatment during the first year after LT. The final number of liver transplant recipients was 133 patients. All included patients were followed prospectively and underwent a liver biopsy 1 year after LT. Paired HVPG determination was also available in 94 patients. In addition, 16 patients who underwent antiviral treatment before LT and did not have hepatitis C recurrence 24, 25 were included as the control group.
In accordance with the ethical guidelines of the 1975 Declaration of Helsinki, the Investigation and Ethics Committee of the Hospital Clinic of Barcelona approved the study.
Clinical Variables
Patients were managed according to previously published protocols. 26 Induction immunosuppression was cyclosporine A or tacrolimus and prednisone. Mycophenolate mofetil was added for those patients who required cyclosporine or tacrolimus dose reduction or discontinuation. Acute rejection episodes were documented by liver histology and were treated with steroid boluses if moderate or severe. 27 After discharge, patients were visited at the outpatient clinic monthly for the first 3 months and every 2-3 months thereafter, at which time clinical and analytical variables were recorded.
Baseline characteristics, HCV genotype and viral load before LT, surgical variables (type of LT, donor age, ischemia time), posttransplantation information, and follow-up were prospectively collected in our liver unit with the use of electronic medical records and clinical history of the patients.
Serum Fibrosis Markers and the 3-Marker Algorithm
To evaluate the accuracy of serum markers to estimate the degree of liver fibrosis we analyzed HA, PIIINP, and TIMP-1 at months 3, 6, and 12 after LT. All patients (n ϭ 133) had serum samples at 3 and 12 months and 96 (72%) at 6 months. We measured the serum markers with a random access automated clinical immunochemistry analyzer that performs the magnetic separation enzyme immunoassay test (Immuno 1TM; Siemens Healthcare Diagnostics, Tarrytown, NY). Serum concentrations of HA, PIIINP, and TIMP-1 were expressed in nanogram per milliliter. The algorithm, including the 3 markers (3-M-ALG) {discriminant score ϭ Ϫ7.412 ϩ [ln (HA) ϫ 0.681] ϩ [ln (PIIINP) ϫ 0.775] ϩ [ln (TIMP-1)] ϫ 0.494} is based on a predictive model derived from a multivariate forward stepwise logistic regression analysis of an independent group of patients 19, 28 and was developed by Siemens Healthcare Diagnostics.
Routine Laboratory Tests and Fibrosis Scores
Aspartate aminotransferase (AST; in IU/L), alanine aminotransferase (ALT; in IU/L), prothrombin time (in seconds), albumin-to-total protein ratio, platelet counts (in 10 9 /L), and 3 validated scores in patients with HCV who received a liver transplant (AST/ALT ratio, 13 AST-to-platelet ratio index [APRI], 13 and Benlloch score 12 ) were evaluated in the same patients at 3, 6, and 12 months after LT to compare the diagnostic accuracy of different tests to estimate the presence of significant fibrosis and portal hypertension.
Liver Biopsies and Paired HVPG Measurements
Percutaneous, transjugular liver biopsies and HVPG measurements were performed as previously described. 7 Samples were processed in the pathology department. An expert pathologist (M.B.) who did not know the HVPG values or serologic marker concentrations scored all histologic samples. Necroinflammatory activity and fibrosis stage were scored by using the Scheuer classification, which classifies liver fibrosis as absent (F0), restricted to the portal tract (F1), periportal or portal-portal septa with intact architecture (F2), bridging fibrosis with architectural distortion but no obvious cirrhosis (F3), and cirrhosis (F4). 29 HVPG measurements were performed as previously reported. 7 Progressive HCV recurrence was defined as the presence of significant fibrosis (F Ն 2) or portal hypertension (HVPG Ն 6 mm Hg) or both 1 year after LT, whereas mild recurrence was defined as absent or minimal fibrosis and normal portal pressure at the same time point.
Statistical Analysis
The sample size was estimated on statistical assumptions based on previous data and designed to obtain a good estimation of diagnostic accuracy of the 48 (58) 27 (54) Other, n (%) 3 (4) 0 (0) CMV infection or CMV illness, n (%) 4 (5) 5 (10) .296 Fibrosis 1 year after LT (Scheuer) .001
-2 (4) NIA 1 year after LT (Scheuer) .001 NIA Ն4, n (%)
29 ( .001 HVPG Ͻ 6, n (%) 52 (90) 11 (31) HVPG 6-6.9, n (%) 4 (7) 10 (28) HVPG Ն 10, n (%)
2 (3) 15 (42) CMV, cytomegalovirus; F, fibrosis stage; HCV, hepatitis C virus; HVPG, hepatic venous pressure gradient; LT, liver transplantation; NIA, necroinflammatory activity. a HVPG Ͻ 6 versus HVPG Ն 6 (P ϭ .001). 30 Quantitative variables are expressed as medians (ranges). Differences between qualitative variables were assessed with the Fisher exact test; concordance was assessed by statistics ( Ͻ 0.4, low; 0.41-0.6, fair; and Ͼ 0.6, good). Differences between quantitative variables were analyzed with a nonparametric test (Mann-Whitney or Kruskal-Wallis for independent samples and Wilcoxon or Friedman for related samples). Correlation between serum markers and HVPG was expressed with the Pearson's correlation. The optimal cutoff values of 3-M-ALG at 6 months were selected on the basis of sensitivity (S), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) to identify patients at risk of developing mild and progressive recurrence. Sample size and comparisons between AUROCs were calculated with the use of MedCalc v9.6.2.0 (MedCalc Software, Mariakerke, Belgium), and the remaining analyses were done with SPSS 12.0 (SPSS Inc, Chicago, IL).
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Results
Patient Characteristics
From May 2000 to July 2006, 195 consecutive patients infected with HCV who received a liver transplant were initially included in the study. Sixty-two patients (32%) were excluded for different reasons. Exclusion criteria were suboptimal biopsies (length Յ 5 mm; n ϭ 8), death (n ϭ 3), or retransplantation (n ϭ 4) earlier than 1 year after LT, moderate or severe acute graft rejection (n ϭ 23), biliary complications (n ϭ 13), and antiviral treatment (n ϭ 11). In these 11 patients liver biopsy before treatment showed F1 in 1 patient, F2 in 4 patients and fibrosing cholestatic hepatitis 31 in 3 patients. Therefore, 133 patients were included and prospectively followed. All underwent a liver biopsy 1 year after LT, and a paired HVPG determination was available in 94 patients (71%).
The median recipient age at the time of LT was 58 years (range, 24 -70 years). Seventy-six patients (57%) were males, and the median donor age was 46 years (range, 11-79 years). LT was from a deceased donor in 118 patients (89%) and from a living donor in 15 patients (11%). The HCV infecting genotype was 1b in 112 patients (84%), 1a in 5 patients (4%), 2 in 2 patients (2%), 3 in 7 patients (5%), 4 in 3 patients (2%), and nontypable in 4 patients (3%). No differences in baseline characteristics were found when comparing patients with or without significant fibrosis (Table 1) . Patients from the control group (n ϭ 16) had a persistent negative HCV-RNA and normal ALT (Ͻ40 IU) concentrations 1 year after LT.
Fibrosis Stage 1 Year After LT and Serum Biomarkers Progression
Liver reperfusion biopsies, performed in all patients, did not show any degree of liver fibrosis. Liver a At 3 months n ϭ 16, at 6 months n ϭ 13, and at 12 months n ϭ 15. b At 3 months n ϭ 83, at 6 months n ϭ 63, and at 12 months n ϭ 83. c At 3 months n ϭ 50, at 6 months n ϭ 33, and at 12 months n ϭ 50. d Median; range in parentheses (all such values).
biopsy 1 year after LT was percutaneous in 39 (29%) and transjugular in 94 (71%) HCV-infected patients. The median length was 17 mm (range, 7-26 mm) in percutaneous biopsies and 15 mm (range, 6 -36 mm) in transjugular biopsies (P ϭ .11). Histologic evidence of rejection was investigated and not detected in any of the liver biopsies performed. All HCV-infected patients showed histologic signs of chronic hepatitis C recurrence 1 year after LT. Liver fibrosis stage, necroinflammatory activity, and hemodynamic data 1 year after LT are summarized in Table  1 . Eighty-three patients (62%) had minimal or absent fibrosis (F0 -F1) and 50 (38%) had significant fibrosis (F Ն 2). Biomarker values at 3, 6, and 12 months were significantly higher in patients developing progressive recurrence than in patients with mild recurrence and HCVnegative patients (Table 2; Figure 1 and 2) . Values of the 3 biomarkers in HCV-negative patients were similar to those with mild hepatitis C recurrence at all time points. At 3 months the AUROCs for diagnosis of significant fibrosis was 0.67 for HA, 0.60 for PIIINP, and 0.67 for TIMP-1. At 6 months the AUROCs were 0.72, 0.78, and 0.75, respectively. Only TIMP-1 showed an improved accuracy 12 months after LT (AUROC, 0.81), whereas that of HA and PIIINP did not change (0.74 and 0.75, respectively). When comparing the AUROCs between PIIINP and HA or TIMP-1 to predict F Ն 2, we did not find significant differences.
To improve the diagnostic accuracy of these biomarkers to identify patients with mild or progressive recurrence, we used 3-M-ALG. 18 The values of 3-M-ALG at 3, 6, and 12 months were significantly higher in patients with pregressive recurrence (F2-4) than in patients with mild hepatitis C recurrence (F0 -1) and HCV-negative patients ( Table 2 ; Figure 1D ). The AUROCs of 3-M-ALG at 3, 6, and 12 months to predict significant fibrosis (F Ն 2) were 0.67, 0.77, and 0.78, being 0.73, 0.84, and 0.85, respectively, to predict advanced fibrosis (F3-4). Whereas 3-M-ALG did not change significantly between 3 and 6 months in HCV-negative patients (P ϭ .07) and in patients with mild hepatitis C recurrence (P ϭ 0.81), 3-M-ALG values significantly increased in patients with pro- 
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gressive recurrence (P ϭ .002). Because the 3-M-ALG values did not change in any group between 6 and 12 months, we chose 6 months as the optimal time point to predict the risk of developing progression recurrence. At this time point, there were no significant differences either in routine laboratory tests or in previously validated fibrosis scores (AST/ALT, APRI, Benlloch) between patients with progressive HCV recurrence and mild recurrence (Supplementary Table 1 ). The AUROCs of the 3 fibrosis scores at 3, 6, and 12 months after LT are shown in Table 3 .
Serum Biomarkers and HVPG Values After LT
A paired HVPG determination was available in 94 patients at the same time as liver biopsy. The proportion of patients with portal hypertension (HVPG Ն 6 mm Hg) (n ϭ 31; 33%) was similar to that of patients with significant fibrosis (F Ն 2) (n ϭ 50; 38%), with a good correlation ( ϭ 0.61) (Figure 2 ).
Similarly, there was a good association between clinically significant portal hypertension (HVPG Ն 10 mm Hg) (n ϭ 17; 18%) and advanced fibrosis (F3-4) (n ϭ 20; 15%) ( ϭ 0.63) 1 year after LT. Figure 2 shows the 3-M-ALG values at 6 and 12 months in patients with and without portal hypertension.
There was a good relationship between biomarker concentrations and HVPG values at 12 months after LT. The Pearson's coefficient for HA, PIIINP, and TIMP-1 one year after LT was 0.64 (P Ͻ .001), 0.65 (P Ͻ .001), and 0.74 (P Ͻ .001), respectively. At 3 months the AUROCs for diagnosis of portal hypertension (HVPG Ն 6 mm Hg) were 0.74 for HA, 0.71 for PIIINP, and 0.74 for TIMP-1 (Table 3) . At 6 months the AUROCs were 0.84, 0.88, and 0.81, respectively. The values at 12 months were 0.87, 0.83, and 0.89, respectively. The AUROCs of 3-M-ALG at 3, 6, and 12 months to predict portal hypertension were 0.75, 0.87, and 0.90, respectively, and to predict clinically significant portal hypertension (HVPG Ն 10 mm Hg) were 0.75, 0.86, and 0.93, respectively. The 3-M-ALG values increased significantly from 3 to 6 months in patients with portal hypertension 1 year after LT (P ϭ .001). As in patients with significant fibrosis, we chose 6 months as the best time point to evaluate the accuracy of 3-MALG to identify patients with portal hypertension. The diagnostic accuracy to identify patients with portal hypertension of the 3 previously published fibrosis scores was significantly lower than that obtained with the 3-M-ALG. Table 3 depicts the AUROCs of these scores at 3, 6, and 12 months.
Accuracy of the 3-M-ALG at 6 Months After LT to Predict the Evolution of Hepatitis C Recurrence
The diagnostic accuracy of 3-M-ALG at 6 months was good to identify patients at risk of developing significant fibrosis (AUROC, 0.77) and excellent to identify patients at risk of developing portal hypertension (AUROC, 0.87). Comparisons of the AUROCs of the 3 previously validated fibrosis scores and the 3-M-ALG are shown in Figure 3A . In addition, the 3-M-ALG cutoff Ͻ 1.8 at 6 months correctly identified 53 patients (84%) with mild fibrosis (S, 58%; Sp, 84%) and a cutoff Ͻ 1.6 identified 35 patients (80%) with normal portal pressure (S, 78%; Sp, 80%). By contrast, a cutoff Ն 3.1 had a specificity of 100% in the diagnosis of patients at risk of developing significant fibrosis (S, 21%), and a cutoff Ն 2.9 showed a Sp of 98% to identify patients at risk of developing portal hypertension 1 year after LT (S, 44%) ( Table 4) .
Accuracy of the 3-M-ALG at 12 Months After LT to Identify Patients With Mild and Progressive Hepatitis C Recurrence
There was a good correlation between 3-M-ALG and HVPG values at 12 months after LT with a Pearson's correlation of 0.704 (P Ͻ .001). The diagnostic accuracy of 3-M-ALG 1 year after LT was good to identify patients with significant or advanced fibrosis (AUROC, 0.78 and 0.85, respectively) and excellent to identify patients with portal hypertension and clinically significant portal hypertension (AUROC, 0.90 and 0.93, respectively). AUROCs of the 3 previously published fibrosis scores are shown in Figure 3B . The optimal cutoff (highest S and Sp) of the 3-M-ALG at 12 months after LT correctly identified 51 patients (61%) with mild fibrosis (NPV, 82%) and 23 patients (46%) with significant fibrosis (PPV, 92%). Moreover, 3-M-ALG identified 42 patients (67%) with normal portal pressure (NPV, 98%) and 20 patients (65%) with portal hypertension (PPV, 83%) 1 year after LT (Table  4) . AUROCs of the 3-M-ALG to identify significant fibrosis and portal hypertension were similar in patients with body mass index (BMI; in kg/m 2 ) Ն 28 (AUROC, 0.75 and 0.89, respectively) compared with patients with BMI Ͻ 28 (AUROC, 0.78 and 0.9, respectively). 
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Accuracy of the 3-M-ALG at 12 Months After LT to Identify Patients at Risk of Developing Clinical Decompensation and Death During the Follow-Up
Thirty-four patients (26%) developed clinical decompensation during 58 months (range, 15-99 months) of follow-up. Nine patients (27%) had F0 -1, 11 patients (32%) had F2, 12 patients (35%) had F3, and only 2 patients (6%) had F4 one year after LT. Among the 99 patients (74%) who did not develop decompensation 74 patients (74%) had F0 -1, 19 patients (19%) had F2, and 6 patients (6%) had F3 one year after LT. As we reported previously, HVPG was more accurate at identifying patients at risk of clinical decompensation, and only 5 (8%) of 63 patients with HVPG Ͻ 6 mm Hg 1 year after LT developed decompensation. 7 3-M-ALG Ն 2.2 at 12 months after LT identified 12 (60%) of 20 patients with advanced fibrosis (F3-4) , and 3-M-ALG Ն 2 identified 15 (88%) of 17 patients with clinically significant portal hypertension (HVPG Ն 10). The AUROC to predict the development of clinical decompensation was 0.84, and a 3-M-ALG Ն 2 at 12 months correctly identified 20 (59%) of 34 patients at risk of developing decompensation (P Ͻ .001, log-rank test) Figure 3 . Diagnostic accuracy of AST/ALT, APRI, Benlloch score, and 3-M-ALG at 6 (A) and 12 (B) months after LT to predict the risk of developing significant fibrosis and portal hypertension. (A) Diagnostic accuracy (AUROC) of 3-M-ALG at 6 months after LT was higher (P Ͻ .05) than APRI and the Benlloch score to identify patients at risk of developing significant fibrosis and higher than the 3 indexes to identify patients at risk of developing portal hypertension. (B) The AUROC of 3-M-ALG at 12 months after LT was higher than the 3 indexes to identify patients with significant fibrosis and higher than APRI and the Benlloch score to identify patients with portal hypertension (Table 3) .
( Figure 4A ). The same cutoff identified 11 (65%) of 17 patients who died as a result of hepatitis C recurrence (P Ͻ .001, log-rank test) during a median follow-up of 58 months (range, 15-99 months) ( Figure 4B ). The accuracy of the 3 fibrosis scores to identify patients at risk of developing clinical decompensation was significantly lower for AST/ALT (0.72; P ϭ .08), APRI (0.51; P Ͻ .001), and Benlloch score (0.56; P ϭ .001) in comparison with the 3-M-ALG.
Discussion
The current study evaluates the accuracy of 3 different markers of fibrosis (PIIINP, HA, and TIMP-1) and 3 fibrosis scores based on routine laboratory tests to identify patients at risk of developing significant fibrosis (F Ն 2), portal hypertension (HVPG Ն 6 mm Hg), or both. The study relies on a prospectively followed cohort of patients with hepatitis C recurrence after LT. Data were obtained in 133 patients infected with HCV who received a liver transplant and 16 patients negative for HCV infection who received a liver transplant (control group), using the 2 current "gold standards": liver biopsy and HVPG measurements. 7, 11 Histologic damage and portal hypertension, 1 year after LT, correlate with the outcome of patients with HCV infection who received a liver transplant and identify those with progressive hepatitis C recurrence. 5, 7 However, an earlier identification of patients at risk of developing rapid fibrosis progression after LT by noninvasive methods could be crucial because antiviral treatment may avoid fibrosis progression. 4, 32 LSM has recently been shown to be an excellent noninvasive method to identify patients with significant fibrosis and portal hypertension 1 year after LT. 10, 11 Nevertheless, its utility at earlier time points has not been studied.
In a retrospective cohort of 46 subjects, Pungpapon et al 14 suggested that serum HA and YKL-40 measured 3-8 months after LT could predict fibrosis progression (increase in Ishak score Ն 2) from the first (3-8 months after LT) to the second (2-4 years after LT) biopsy. However, this preliminary study had some methodologic limitations, 33 including the lack of a control group.
The current study shows several important results. Biomarker concentrations were significantly higher in patients with progressive hepatitis C recurrence than in patients with mild recurrence and who were HCV negative, starting at very early time points after LT. Despite all the possible variables that can contribute to an increase in the inflammatory activity, such as vascular or biliary problems, acute rejection or viral hepatitis (cytomegalovirus, Epstein-Barr virus, etc), the HCV-negative group showed a minimal increase in fibrosis biomarkers during the first year after LT. In contrast, progressive hepatitis C recurrence seems to be the most important trigger for fibrosis activation. 34 However, note that the high dispersion of these biomarkers 3 months after LT did not allow F, fibrosis stage; HVPG, hepatic venous pressure gradient; LRϩ, likelihood ratio positive; LRϪ, likelihood ratio negative; LT, liver transplantation; PPV, positive predictive value; NPV, negative predictive value; OR, odds ratio; S, sensitivity; Sp, specificity; 95% CI, 95% confidence interval; 3-M-ALG: 3-marker algorithm.
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accurate discrimination between patients with mild or progressive recurrence at this time point. By contrast, serum biomarker concentrations at 6 and 12 months discriminated patients with mild and progressive HCV recurrence, with 6 months being the best time point to predict the risk of progressive hepatitis C recurrence. The combination of the 3 biomarkers in an algorithm (3-M-ALG) 19, 28 significantly increased their prediction accuracy. The 3-M-ALG at 6 months was able to identify almost one-half of the patients who developed portal hypertension 1 year after LT (PPV, 89%), and at 12 months it identified 88% of patients with clinically significant portal hypertension (HVPG Ն 10). In contrast, previously published fibrosis scores 12, 13 showed a lower accuracy to identify patients at risk of developing significant fibrosis or portal hypertension because some of the variables included can be altered by causes not related to fibrosis progression, especially during the first months after LT. 7, 11 As stated earlier, initiation of antiviral therapy at an earlier time point in these patients might prevent the development of significant fibrosis, portal hypertension, clinical decompensation (synonymous with graft loss), and death. The 3-M-ALG at 6 months was also accurate at identifying most patients with mild fibrosis (NPV, 79%) and normal portal pressure (NPV, 90%) 1 year after LT. These results, if validated, suggest that biomarkers could be useful to monitor HCV recurrence in the transplantation setting and to decide the best therapeutic strategy in these patients. In patients with a 3-M-ALG Ͻ 1.6 six months after LT, follow-up would be appropriate because 90% of these patients show slow disease progression. In contrast, in patients with a 3-M-ALG Ն 2.9, antiviral treatment should be considered at an early stage because 89% develop portal hypertension at 1 year. Nevertheless, if antiviral treatment is indicated, a liver biopsy before treatment initiation is still necessary to exclude other causes of liver dysfunction. 33 The accuracy of these markers was very good at identifying patients with progressive recurrence 1 year after LT. In the case of patients with portal hypertension, there was a good correlation between 3-M-ALG and HVPG values (r ϭ 0.70) and the accuracy was similar (AUROC, 0.90) to that previously reported with LSMs (AUROC, 0.93). 11 Despite the excellent accuracy of LSMs for identification of patients with progressive hepatitis C recurrence, it is important to note that TE cannot be performed in patients with a high BMI, whereas this parameter, which can change after LT, does not seem to influence serum marker measurements. In addition, TE is not available in all LT units. The combination of TE and serum fibrosis biomarkers might further increase the accuracy of noninvasive assessment of significant fibrosis/portal hypertension. In fact, a 3-M-ALG cutoff Ͻ 1 identified 67% of patients with normal portal pressure. This cutoff showed a high NPV (98%) because among the 43 patients with values below this cutoff only 1 patient had portal hypertension. Therefore, the avoidance of liver biopsy in the follow-up of these patients could be a rational strategy, particularly if antiviral treatment is not considered. By contrast, a 3-MALG cutoff Ն 2 identified 65% of patients with portal hypertension and showed a PPV of 83% (only 4 of 24 patients with a 3-M-ALG Ն 2 did not have portal hypertension). Moreover a 3-M-ALG Ն 2 one year after LT identified patients with a high risk of developing clinical decompensation and death. Therefore, patients with 3-M-ALG Ն 2 should be considered for liver biopsy and early antiviral therapy.
It is evident that the results of the current study and the proposed strategies require external validation in a large prospective cohort of liver transplant patients. In addition, our results show some dispersion in serum marker determinations, especially during the first months after transplantation. Finally, although the accuracy at excluding patients at risk of developing severe fibrosis and portal hypertension is very high, early detection of patients who will develop progressive recurrence (and in whom antiviral therapy is warranted) is not optimal. Although an alternative management strategy could be protocol liver biopsies at months 6 and 12 after LT, the combination of serum markers with other noninvasive estimations of liver fibrosis (such as TE) should be investigated. Further studies are needed to confirm the superior predictive value of noninvasive methods over liver biopsy.
In summary, serum fibrosis markers measured during the first months after LT identify patients with mild and progressive hepatitis C recurrence. More importantly, a simple score (3-M-ALG), including HA, PIIINP, and TIMP-1, at 6 months after LT can accurately predict patients with mild recurrence and patients at risk of developing significant fibrosis and portal hypertension. This could be relevant to adopt therapeutic decisions at an early stage. These results should be validated in a large cohort of patients who have received a liver transplant, and the combination of 3-M-ALG with other noninvasive methods should be investigated.
